TY - JOUR
T1 - Safety of bevacizumab in clinical practice for recurrent ovarian cancer
T2 - A retrospective cohort study
AU - Selle, Frèdèric
AU - Emile, George
AU - Pautier, Patricia
AU - Asmane, Irène
AU - Soares, Daniele G.
AU - Khalil, Ahmed
AU - Alexandre, Jerome
AU - Lhomme, Catherine
AU - Ray-Coquard, Isabelle
AU - Lotz, Jean Pierre
AU - Goldwasser, François
AU - Tazi, Youssef
AU - Heudel, Pierre
AU - Pujade-Lauraine, Eric
AU - Gouy, Sèbastien
AU - Tredan, Olivier
AU - Barbaza, Marie O.
AU - Ady-Vago, Nora
AU - Dubot, Coraline
N1 - Publisher Copyright:
© Spandidos Publications 2016.
PY - 2016/3/1
Y1 - 2016/3/1
N2 - The poor outcome of patients with recurrent ovarian cancer constitutes a continuous challenge for decision-making in clinical practice. In this setting, molecular targets have recently been identified, and novel compounds are now available. Bevacizumab has been introduced for the treatment of patients with ovarian cancer and is, to date, the most extensively investigated targeted therapy in this setting. However, potential toxicities are associated with the use of this monoclonal antibody. These toxicities have been reported in clinical trials, and can also be observed outside of trials. As limited data is currently available regarding the safety of bevacizumab treatment in daily clinical practice, the current retrospective study was designed to evaluate this. Data from 156 patients with recurrent ovarian cancer who had received bevacizumab treatment between January 2006 and June 2009 were retrospectively identified from the institutional records of five French centers. In contrast to clinical trials, the patients in the present study were not selected and had a heterogeneous profile according to their prior medical history, lines of treatment prior to bevacizumab introduction and number of relapses. The results first confirm the effect of heavy pretreatment on the occurrence of serious and fatal adverse events in clinical practice, as previously reported for clinical trials and for other retrospective cohort studies. Importantly, the data also demonstrates, for the first time, that medical history of hypertension is an independent predictive risk factor for the development of high-grade hypertension during bevacizumab treatment. These results thus suggest that treating physicians must consider all risk factors for managing bevacizumab toxicity prior to its introduction. Such risk factors include the time of bevacizumab introduction, a patient's history of hypertension and a low incidence of pre-existing obstructive disease.
AB - The poor outcome of patients with recurrent ovarian cancer constitutes a continuous challenge for decision-making in clinical practice. In this setting, molecular targets have recently been identified, and novel compounds are now available. Bevacizumab has been introduced for the treatment of patients with ovarian cancer and is, to date, the most extensively investigated targeted therapy in this setting. However, potential toxicities are associated with the use of this monoclonal antibody. These toxicities have been reported in clinical trials, and can also be observed outside of trials. As limited data is currently available regarding the safety of bevacizumab treatment in daily clinical practice, the current retrospective study was designed to evaluate this. Data from 156 patients with recurrent ovarian cancer who had received bevacizumab treatment between January 2006 and June 2009 were retrospectively identified from the institutional records of five French centers. In contrast to clinical trials, the patients in the present study were not selected and had a heterogeneous profile according to their prior medical history, lines of treatment prior to bevacizumab introduction and number of relapses. The results first confirm the effect of heavy pretreatment on the occurrence of serious and fatal adverse events in clinical practice, as previously reported for clinical trials and for other retrospective cohort studies. Importantly, the data also demonstrates, for the first time, that medical history of hypertension is an independent predictive risk factor for the development of high-grade hypertension during bevacizumab treatment. These results thus suggest that treating physicians must consider all risk factors for managing bevacizumab toxicity prior to its introduction. Such risk factors include the time of bevacizumab introduction, a patient's history of hypertension and a low incidence of pre-existing obstructive disease.
KW - Bevacizumab
KW - Clinical practice
KW - Hypertension
KW - Recurrent ovarian cancer
KW - Safety
UR - http://www.scopus.com/inward/record.url?scp=84958063735&partnerID=8YFLogxK
U2 - 10.3892/ol.2016.4146
DO - 10.3892/ol.2016.4146
M3 - Article
AN - SCOPUS:84958063735
SN - 1792-1074
VL - 11
SP - 1859
EP - 1865
JO - Oncology Letters
JF - Oncology Letters
IS - 3
ER -